Nature Biotechnology, Published online: 13 July 2026; doi:10.1038/s41587-026-03218-w
DeepDETAILS enables cross-modality deconvolution of bulk sequencing samples.
Category Added in a WPeMatico Campaign
Nature Biotechnology, Published online: 13 July 2026; doi:10.1038/s41587-026-03218-w
DeepDETAILS enables cross-modality deconvolution of bulk sequencing samples.
Nature Medicine, Published online: 13 July 2026; doi:10.1038/s41591-026-04518-z
In a phase 1 trial, treatment with the antibody−drug conjugate DYP688, targeting PMEL and delivering a Gq/11 inhibitor, in patients with GNAQ/GNA11-mutant metastatic uveal melanoma or other GNAQ/GNA11-mutant melanomas, showed acceptable safety and encouraging preliminary efficacy, with supporting biomarker data for proof of mechanism.
An international team of scientists report that they have successfully mapped the cells and genes that regulate bone formation and loss and discovered the critical role that blood vessel cells play in bone health. By combining genomic sequencing with data from half a million individuals, the research team identified hundreds of previously unknown genes that govern bone health and revealed cells surrounding blood vessels as one of the drivers of bone repair.
The study “Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease” is published in Nature Genetics. The team says its findings fundamentally enhance our understanding of skeletal disease. It is hoped the discovery will enable the development of new therapies to rebuild lost bone, offering hope to almost half of all individuals over 50 living with rare and common skeletal conditions such as osteoporosis, osteoarthritis and osteogenesis imperfecta, as well as those with rare bone disorders and cancers that spread to bone.
“Most people don’t realize that bones are constantly changing; the human body replaces its skeleton every 10 years or so,” said Peter Croucher, PhD, professor at the Garvan Institute of Medical Research in Australia. “This is a hugely important process, but until now we’ve had a limited understanding of the cells and mechanisms that control this turnover of bone. “Most of the drugs now available focus only on halting bone disease, rather than rebuilding lost bone, which is really important for reversing damage.”
The team used single-cell RNA sequencing to measure which genes are switched on within individual cells found in bone, focusing on the interface between the hard bone and bone marrow which is the key site for the formation and breakdown of bone.
The Institute’s Ryan Chai, PhD, pointed out that the team’s analysis found 34 different groups of cells and defined the genes that are active in each of these cell types. “To our surprise, more than half of the genes identified have never before been shown to play a role in maintaining bone health, which is a significant finding,” he added.
![Ryan Chai, PhD, and Peter Croucher, PhD, from the Garvan Institute of Medical Research. [Garvan Institute]](https://www.genengnews.com/wp-content/uploads/2026/07/Low-Res_141A8709_Peter_C_Ryan_C-300x200.jpg)
The team used its map to identify cells involved in rare and common skeletal diseases, including osteogenesis imperfecta and osteoporosis. For the latter, the researchers analyzed the UK Biobank, one of the world’s biggest and most comprehensive collections of biological samples.
By analyzing genetic and bone density data from half a million people participating in the UK Biobank, the team was able to pinpoint exactly which cells drive skeletal disease, according to John Kemp, PhD, associate professor from Mater Research.
“These include cells known to regulate bone formation and bone loss, as well as blood vessel cells that, until now, have had underappreciated roles in bone health,” he said.
Croucher explained that the research uncovered new therapeutic opportunities against not only bone disease, but also cancer. “Bone is the main hiding place for dormant cancer cells and a common site of relapse, so identifying the cells and genes that drive bone turnover also opens new opportunities to prevent cancer metastasis,” he said.
The team is now further investigating the roles of newly discovered bone-regulating cells and genes in the hope of developing new medicines against these targets. Its data has been made accessible to medical researchers worldwide through an open access platform.
The post Genetic Map Opens Door to Development of New Therapies to Reverse Bone Loss appeared first on GEN – Genetic Engineering and Biotechnology News.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. In case you missed it, my pal Bob Herman got the Joe Kernan treatment on CNBC’s “Squawk Box” on Friday, where he discussed his excellent new series “Out of Pocket, Out of Reach.” Kernan got in a lot of digs at Democrats and Obamacare, but Bob kept his comments apolitical. A true professional!
On three of my last seven flights, a request came over the cabin speakers: “Is there a doctor on board?” Like many physicians, I responded automatically.
What struck me afterward was not the frequency of those requests but how unremarkable the whole process seemed — to the crew, to other passengers, and, eventually, to me. None of the patients were in cardiac arrest. The complaints were the kind that fill any urgent care waiting room on a Tuesday afternoon: dizziness, nausea, feeling faint, generalized malaise.
LONDON — When researchers started planning a pancreatic cancer conference here, the aim was to simply offer a counterpart to a regular U.S. meeting, where international scientists and doctors could discuss the latest developments in the specialty.
Then came the biggest shake-up in pancreatic cancer care in decades.
“It’s one of those moments,” Talia Golan, an oncologist at Israel’s Sheba Medical Center, said on a panel that conference organizers hastily added to the schedule centered on a new pancreatic cancer drug. She likened the medicine’s recent clinical trial performance to other milestones in cancer treatment such as the arrival of the first checkpoint inhibitors.
In 2018, Kristine Fifer was lucky to avoid bankruptcy.
Her son, Eddie, had lost the nurse provided to him by the state after he turned 22. Maryland health officials told Fifer that he didn’t qualify for nursing care, even though Eddie’s cerebral palsy, feeding tube, and other complex medical conditions require around-the-clock care. Fifer spiraled as she sought to pay for the care Eddie needed. She lost her job, took on heaps of debt as bills piled up, and eventually called a lawyer about filing for bankruptcy.
WASHINGTON — Health secretary Robert F. Kennedy Jr. is pressing forward with his effort to help Americans stop taking psychiatric drugs, a medical practice known as deprescribing.
Earlier this month, dozens of mental health professionals met with federal health officials to map out forthcoming clinical guidance they hope will help providers instruct patients on how to come off of antidepressant medications. While the Department of Health and Human Services has discussed plans to hold such a meeting, the outlines of the discussion haven’t been reported.
During those talks, they reviewed guidance from European nations and worked on recommendations for nonmedication-based options for patients to address their mental health, such as therapy. A senior HHS official said they discussed gaps in the research around deprescribing SSRIs, including the side effects a person may experience, which vary depending on the drug and how long the person was on it, and how to recognize the difference between those side effects and a return of a patient’s depressive symptoms.